Analyzing Prenetics Global (NASDAQ:PRE) and PositiveID (OTCMKTS:PSID)

PositiveID (OTCMKTS:PSID) and Prenetics Global (NASDAQ:PRE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Institutional and Insider Ownership

25.0% of Prenetics Global shares are owned by institutional investors. 48.4% of PositiveID shares are owned by insiders. Comparatively, 7.8% of Prenetics Global shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares PositiveID and Prenetics Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PositiveID	N/A	N/A	N/A
Prenetics Global	-191.73%	-16.45%	-13.34%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for PositiveID and Prenetics Global, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PositiveID	0	0	0	0	0.00
Prenetics Global	0	0	1	0	3.00

Prenetics Global has a consensus target price of $9.00, suggesting a potential upside of 66.20%. Given Prenetics Global’s stronger consensus rating and higher probable upside, analysts clearly believe Prenetics Global is more favorable than PositiveID.

Earnings and Valuation

This table compares PositiveID and Prenetics Global”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PositiveID	N/A	N/A	N/A	N/A	N/A
Prenetics Global	$25.56 million	2.59	-$62.72 million	($3.99)	-1.36

PositiveID has higher earnings, but lower revenue than Prenetics Global.

Summary

Prenetics Global beats PositiveID on 5 of the 9 factors compared between the two stocks.

About PositiveID

PositiveID Corporation, a life sciences and technology company, develops and sells molecular diagnostic systems for bio-threat detection and medical testing in the United States and internationally. It operates through three segments: Molecular Diagnostics, Medical Devices, and Mobile Labs. The company develops microfluidic systems for the automated preparation and performance of biological assays to detect biological threats and analyze biological samples at the point of need. It has a portfolio of intellectual property related to sample preparation and rapid medical testing applications. The company's microfluidic bio-agent autonomous networked detector (M-BAND) technology is a bio-aerosol monitor with integrated systems for sample collection, processing, and detection modules. Its M-BAND technology analyzes air samples for the detection of pathogenic bacteria, viruses, and toxins for up to 30 days. The company's FireflyDX is an automated pathogen detection system for rapid diagnostics for clinical and point-of-need applications. Its FireflyDX system detects and identifies common pathogens and diseases, such as E. coli, methicillin-resistant staphylococcus aureus, methicillin-susceptible staphylococcus aureus, clostridium difficile, Zika virus, Ebola virus, influenza, and others. In addition, PositiveID Corporation markets Caregiver, a non-contact clinical thermometer that measures forehead temperature in adults, children, and infants for hospitals, physicians' offices, medical clinics, nursing homes and other long-term care institutions, and acute care hospitals; and manufactures and sells specialty technology vehicles for mobile laboratory, command and communications applications, and mobile cellular systems. The company was formerly known as VeriChip Corporation and changed its name to PositiveID Corporation in November 2009. PositiveID Corporation was founded in 2001 and is headquartered in Delray Beach, Florida.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.